HeyJaredMultiple Myeloma Hub
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma.
- Indexed episodes, last 90 days
- 4
- Latest publication
- Sep 15, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 17, 2026
Latest episodes
Belantamab mafodotin in RRMM: Latest updates and practical considerations (opens the original)
Read excerpt
The Multiple Myeloma Hub spoke with Christoph Renner, University of Basel, Basel, CH. We asked about the use of belantamab mafodotin-based combination therapy for relapsed/refractory multiple myeloma (RRMM). During this interview, Renner provides an overview of pivotal clinical data from the DREAMM-7 and DREAMM-8 trials that supported regulatory approvals of belantamab mafodotin-based combinations in RRMM and outlines practical considerations for their use in clinical practice. Renner discusses
How to manage toxicities associated with bispecific antibody therapy for MM in community practice (opens the original)
Read excerpt
The Multiple Myeloma Hub spoke with María-Victoria Mateos, University Hospital of Salamanca, ES. We asked about the management of toxicities associated with bispecific antibody therapy for multiple myeloma (MM) in community practice. In this interview, Mateos discusses practical considerations for the management of adverse events (AEs) associated with bispecific antibodies in MM. Mateos outlines how to recognize and manage cytokine release syndrome (CRS) and immune effector cell-associated neuro
How to transition patients to community-based bispecific antibody therapy (opens the original)
Read excerpt
The Multiple Myeloma Hub spoke with Shaji Kumar, Mayo Clinic, Rochester, US. We asked about transitioning patients to community-based bispecific antibody therapy. In this interview, Kumar discusses practical considerations for transitioning bispecific antibody therapy to community-based practice in patients with multiple myeloma. Kumar outlines strategies for monitoring and managing treatment-related toxicities, including cytokine release syndrome, neurological toxicities, cytopenias, and infect
EHA2026 | DREAMM-8: Early RRMM and sustained MRD-negativity subgroup analyses (opens the original)
Read excerpt
During the European Hematology Association (EHA) 2026 Congress, June 11–14, 2026, Stockholm, SE, the Multiple Myeloma Hub spoke with Meral Beksaç, Istinye University Ankara Liv Hospital, Ankara, TR. We asked about the key findings from two subgroup analyses of the phase III DREAMM-8 trial in RRMM. The first analysis explored outcomes among patients who received only one prior LoT, while the second examined outcomes in patients who achieved sustained MRD negativity. This educational resource is i
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.